Accelerate the establishment of innovative medical equipment, Shanghai strives to reach 1.2 trillion yuan in biomedicine by 2025

 Shanghai will speed up the landing of innovative medical equipment in Shanghai, and make every effort to promote the high-quality development of the biomedical industry
.
On September 26, at the press conference of "2021 Shanghai International Biopharmaceutical Industry Week", Zhang Qing, deputy director of the Shanghai Municipal Drug Administration, said this
.
It is reported that this year's "Shanghai International Biopharmaceutical Industry Week" will showcase the development advantages and supporting policies of Shanghai's biopharmaceutical industry, promote the collision and in-depth exchange of ideas among all parties, and attract the convergence of global advantageous resources
.
Statistics show that in 2020, the scale of Shanghai's biomedical industry will exceed 600 billion yuan, a record high
.
In the first half of 2021, the scale of Shanghai's biopharmaceutical industry increased by 22.
8% year-on-year to 350 billion yuan; 3 local sci-tech innovation board listed companies were newly added, reaching 15 in total
.
By 2025, Shanghai strives to reach 1.
2 trillion yuan in the scale of the biomedical industry
.
It is understood that in the past two years, Shanghai’s biopharmaceutical industry has developed rapidly, with a total of 12 approved domestically-made innovative drugs of category 1 and 6 of them have been approved this year, a record high, accounting for about 4 of the national total.
One part
.
Including China's first small molecule inhibitor specifically targeting MET kinase (Sivotinib tablets from Hutchison Whampoa), and two cell therapy (CAR-T) products (Fosun Kate's Akirensai injection And WuXi Giant Nuo’s Ruiji Oranxel injection).
In terms of medical devices, a total of 58 products in Shanghai have entered the special approval channel for national innovative medical devices in the past two years, 22 of which have been approved for marketing.
This year Nine products in Shanghai have entered the national special approval channel for innovative medical devices, accounting for about one-fifth of the country's total
.
Biomedicine is one of the three leading industries in Shanghai.
At present, Shanghai is based on the development of the biomedical industry.
It is focusing on breakthroughs in advantageous areas, innovation and strategy guidance, key regional development, industrial ecological construction and leading enterprise building, and accelerate the establishment of "R&D" +Clinical + manufacturing + application" the whole industry chain policy support system, continue to improve the space layout of the "1+5+X" biomedicine industry, take multiple measures to promote "Zhangjiang R&D + Shanghai manufacturing", and achieve new breakthroughs in industrial scale
.
According to reports, during the "14th Five-Year Plan" period, Shanghai will grasp the general direction and trend of the booming global bio-economy, cultivate and expand the biomedical industry cluster, and continue to make efforts in three aspects: 1.
Accelerate the research on core technologies; 2.
Strengthen Layout in frontier fields; 3.
Accelerate the transformation of innovation achievements
.
For example, Shanghai will strengthen research and industrialization breakthroughs in areas such as innovative drugs, high-end medical devices, high-end preparations, advanced technology, and urgently needed medical supplies for public health, and support enterprises to cooperate with universities, scientific research institutes, and medical institutions to carry out high-quality collaborative innovation
.
In order to better promote the development of the biomedical industry, Shanghai has also continuously introduced new policy support in recent years
.
For example, from June 1st, Shanghai’s newly issued "Several Opinions on Promoting the High-Quality Development of the Biomedical Industry in the City" (hereinafter referred to as "Opinions") formally implemented.
These 29 articles have been researched and formulated by Shanghai’s 16 departments.
The opinion puts forward that Shanghai will, through three years of hard work, strive to reach 180 billion yuan in annual industrial output value of the city’s biomedical manufacturing industry, focusing on supporting the development of four major industries including innovative drugs, high-end medical devices, advanced biomedical equipment and materials, and new service outsourcing.

.
This year is the first year of the "14th Five-Year Plan".
It is also the first year for the construction of the Shanghai Science and Technology Innovation Center to move from consolidating the framework foundation to building a new stage of core functions.
Enhance innovation capabilities, continuously improve the industrial service system, promote the in-depth integration of industry and medicine, continue to create a better industrial development ecology, and strive to build a world biomedical industry cluster, in order to further enhance innovation sources and high-end industry leadership functions, and accelerate construction with global influence The powerful scientific and technological innovation center provides important support
.
Zhang Qing said that in the next step, the Shanghai Drug Administration will continue to focus on Shanghai's decision-making and deployment to promote the development of the biopharmaceutical industry, actively seek support and guidance from the State Drug Administration, promote continuous optimization of the business environment with innovative services, and fully promote the biopharmaceutical industry.
High-quality development
.
At the same time, it urges enterprises to continuously improve their quality management level, and strengthen safety locks for the citizens to use drugs
.